Investigation of Cisplatin-Related Kidney Toxicity

Prospective Analysis Group

Inclusion Criteria:

Patients about to receive intravenous cisplatin for the first time as part of cancer chemotherapy.
Aged 18 years and older.
Ability to understand and willingness to sign a written consent document.
Patients may be receiving cisplatin in combination with other chemotherapeutic agents.
Patients may be receiving cisplatin in the context of another clinical trial.

Exclusion Criteria:

Prior receipt of cisplatin.
Patients on dialysis or other renal replacement therapy prior to starting cisplatin.
Uncontrolled hypo- or hyperthyroidism (patients on chronic stable doses of thyroid replacement medication are eligible).

Retrospective Analysis Group

Inclusion Criteria:

Patients that have previously received intravenous cisplatin as part of cancer chemotherapy.
Aged 18 years and older.
Ability to understand and willingness to sign a written consent document.
Patients that received cisplatin in combination with other chemotherapeutic agents are eligible.
Patients that received cisplatin in the context of a clinical trial are eligible.

Exclusion Criteria:

Unable or unwilling to submit to a one-time blood draw.